Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...
Despite the importance of downstream bioprocessing, there are many opportunities for improvement, according to a report by Alois Jungbauer, PhD, a retired professor of biotechnology at the University ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results